Flare in spondyloarthritis: Thresholds of disease activity variations

Joint Bone Spine

Volumn 82, Issue 3, 2015, Pages 192-195

  Godfrin Valnet, Marie ^a   Puyraveau, Marc ^a   Prati, Clément ^a   Wendling, Daniel ^a,b  

^a UNIVERSITY HOSPITAL OF BESANÇON   (France)

^b Hôpital Saint Jacques   (France)

Author keywords

Disease activity; Flare; Spondyloarthritis

Indexed keywords

C REACTIVE PROTEIN; HLA B27 ANTIGEN;

ADULT; ANKYLOSING SPONDYLITIS DISEASE ACTIVITY SCORE; ARTICLE; BATH ANKYLOSING SPONDYLITIS DISEASE ACTIVITY INDEX; CLINICAL ASSESSMENT; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE ACTIVITY; DISEASE DURATION; DISEASE EXACERBATION; FEMALE; HUMAN; KAPPA STATISTICS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PERCEPTION; PHYSICIAN; PREDICTIVE VALUE; PROSPECTIVE STUDY; RECEIVER OPERATING CHARACTERISTIC; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; SPONDYLARTHRITIS; DISEASE COURSE; PATHOPHYSIOLOGY; SEVERITY OF ILLNESS INDEX;

ADULT; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; SPONDYLARTHRITIS;

EID: 84929262920     PISSN: 1297319X     EISSN: 17787254     Source Type: Journal    
DOI: 10.1016/j.jbspin.2014.12.008     Document Type: Article

References (12)

1. Wendling D., Lukas C., Paccou J., et al. Recommendations of the French Society for Rheumatology (SFR) on the everyday management of patients with spondyloarthritis. Joint Bone Spine 2014, 81:6-14.
2. Smolen J.S., Braun J., Dougados M., et al. Treating spondyloarthritis, including ankylosing spondylitis and psoriaticarthritis, to target: recommendations of an international task force. Ann Rheum Dis 2014, 73:6-16.
3. Brophy S., Calin A. Definition of disease flare in ankylosingspondylitis: the patients' perspective. J Rheumatol 2002, 29:954-958.
4. Stone M.A., Pomery E., Keat A., et al. Assessment of the impact of flares in ankylosing spondylitis disease activity using the Flare illustration. Rheumatology 2008, 47:1213-1218.
5. Cooksey R., Brophy S., Gravenor M.B., et al. Frequency and characteristics of disease flares in ankylosing spondylitis. Rheumatology 2010, 49:929-932.
6. Rudwaleit M., Van Der Heidje D., Landewé R., et al. The development of assessment of spondyloarthritis international society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis 2009, 68:777-783.
7. Rudwaleit M., Van der Heidje D., Landewé R., et al. The assessment of spondyloarthritis international society classification criteria for peripheral spondyloarthritis and for spondyloarthritisin general. Ann Rheum Dis 2011, 70:1-3.
8. Spoorenberg A., van Tubergen A., LandewéR, et al. Measuring disease activity inankylosing spondylitis: patient and physician have different perspectives. Rheumatology (Oxford) 2005, 44:789-795.
9. Machado P., Landewé R., Lie E., et al. Ankylosing Spondylitis Disease Activity Score (ASDAS): defining cut-off values for disease activitystates and improvement scores. Ann Rheum Dis 2011, 70:47-53.
10. Godfrin-Valnet M., Prati C., Puyraveau M., et al. Evaluation of spondylarthritis activity by patients and physicians: ASDAS, BASDAI, PASS, and flares in 200 patients. Joint Bone Spine 2013, 80:393-398.
11. Song I.H., Heldmann F., Rudwaleit M., et al. One-year follow-up of ankylosing spondylitis patients responding to rituximab treatment and re-treated in case of a flare. Ann Rheum Dis 2013, 72:305-306.
12. Haibel H., Heldmann F., Braun J., et al. Long-termefficacy of adalimumab after drug withdrawal and retreatment in patients withactive non-radiographically evident axial spondyloarthritis who experience a flare. Arthritis Rheum 2013, 65:2211-2213.